|
| Press Releases |
|
 |
|
| Tuesday, December 2, 2025 |
|
|
GEN 宣布針對阿茲海默症及其他神經退化性疾病之試驗藥物 SUL-238 取得全新第一期試驗正面數據 |
| 土耳其領先的專業製藥公司GEN Pharmaceuticals（GENIL.IS）今日宣布，其針對首創口服型線粒體靶向藥物候選物 SUL-238 於健康老年志願者中進行的安全性、耐受性及藥代動力學（PK）評估之第一期臨床試驗取得新進展。該研究成果於今日在美國加州聖地牙哥舉行的第 18 屆阿茲海默症臨床試驗大會（CTAD）發表。 more info >> |
|
|
GEN 宣布针对阿尔茨海默病及其他神经退行性疾病的试验性药物 SUL-238 取得新的积极 I 期临床试验数据 |
| 土耳其领先的专科制药公司GEN Pharmaceuticals（GENIL.IS）宣布，其针对首创口服线粒体靶向药物候选物 SUL-238 的安全性、耐受性和药代动力学（PK）的 I 期临床试验在健康老年志愿者中取得新的积极结果。该研究成果于今日在美国加利福尼亚州圣地亚哥举行的第 18 届阿尔茨海默病临床试验大会（CTAD）上公布。 more info >> |
|
|
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases |
| GEN Pharmaceuticals (GENIL.IS), Turkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. more info >> |
|
| Tuesday, July 29, 2025 |
|
|
GEN 與 Sulfateq BV 公佈治療阿茲海默症及其他神經退化性疾病的候選藥物 SUL-238 的第一階段臨床試驗正面結果 |
| GEN製藥公司（GENIL.IS）是土耳其領先的專業製藥公司，日前宣布其第一階段臨床試驗取得積極結果。該試驗旨在評估首創且新型的口服線粒體靶向候選藥物 SUL-238 在健康老年志願者中的安全性、耐受性以及藥代動力學（PK）表現。研究結果已在2025年阿茲海默症協會國際會議（AAIC®）上於多倫多公佈。 more info >> |
|
|
GEN 与 Sulfateq BV 公布治疗阿尔茨海默病及其他神经退行性疾病的候选药物 SUL-238 的第一阶段临床试验积极结果 |
| GEN制药公司（GENIL.IS）是土耳其领先的专业制药公司，日前宣布其第一阶段临床试验取得积极结果。该试验旨在评估首创且新型的口服线粒体靶向候选药物 SUL-238 在健康老年志愿者中的安全性、耐受性以及药代动力学（PK）表现。研究结果已在2025年阿尔茨海默病协会国际会议（AAIC®）上于多伦多公布。 more info >> |
|
| Monday, July 28, 2025 |
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases |
| more info >> |
|
| Wednesday, September 25, 2024 |
|
|
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis |
| GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
美國馬球協會擴大大學合作計畫 2026賽季隊伍數創紀錄達70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
美国马球协会扩大大学合作计划，2026赛季参赛队伍创纪录达70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 5, 2026 20:00 HKT/SGT
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 17:00: JST
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 16:00 HKT/SGT
|
|
|
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 5, 2026 16:47 JST
|
|
|
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 5, 2026 16:38 JST
|
|
|
Galaxy Corporation Leads "K-Entertech" IPO Rush as Nasdaq Vice Chairman's Surprise Visit Boosts Listing Prospects
Mar 5, 2026 15:30 HKT/SGT
|
|
|
康哲药业自研INHBE小核酸药物获批超重/肥胖临床
Mar 5, 2026 15:13 HKT/SGT
|
|
|
康哲藥業自研INHBE小核酸藥物獲批超重/肥胖臨床
Mar 5, 2026 15:02 HKT/SGT
|
|
|
Formerra 任命 Tom Kelly 為首席執行官
Mar 5, 2026 14:11 HKT/SGT
|
|
|
富士通Japan、大分市民図書館において「デジタル認証アプリ」を活用したWeb利用者登録サービスを構築し、運用を開始
Mar 5, 2026 13:25: JST
|
|
|
Honda、米国生産乗用車の日本導入を決定
Mar 5, 2026 12:50: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
